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Abstract 
Background: Use of allogeneic cancer cells‑based immunotherapy for treatment of established prostate cancer 
(PCa) has only been marginally effective. One reason for failure could stem from the mismatch of antigenic signatures 
of vaccine cells and cancer in situ. Hence, it is possible that vaccine cells expressed antigens differently than tumor 
cells in situ. We hypothesized that cells grown in vitro at low oxygen tension (pO2) provide a better antigen match to 
tumors in situ and could reveal a more relevant antigenic landscape than cells grown in atmospheric pO2.
Methods: We tested this hypothesis by comparing PCa cells propagated at pO2 = 2 kPa and 20 kPa. To identify 
potential tumor‑associated antigens (TAAs), we prepared PCa cell lysates, resolved them by two‑dimensional electro‑
phoresis and immunoblotting using spontaneous antibodies from plasma derived from PCa patients and control sub‑
jects. Antibody‑labeled spots were analyzed by MALDI‑TOF mass spectrometry and validated by ELISA. We selected 
hypoxia‑regulated HSP70 and hnRNP L and hypoxia‑independent HSP60 and determined the frequency of plasma 
samples reacting with these molecules.
Results: Frequency of HSP60‑reactive plasma was low in healthy controls [1.3 % (1/76)], while it was elevated in PCa 
patients [13.0 % (7/54); p < 0.05]. These data suggest a humoral immune response to HSP60 in PCa. Levels of autoan‑
tibodies to HSP70 did not differ from healthy controls [3.7 % (2/54)] in PCa patients [5.3 % (2/38)]. Similarly, hnRNP L 
autoantibodies did no differ between healthy controls [6.1 % (3/49)] and PCa patients [5.3 % (2/38)].
Conclusions: Overall our results suggest the value of hypoxia as a modifier of the cellular and antigenic landscape of 
PCa cells. By modifying the immune reactivity of PCa cells in culture, manipulation of pO2 can be proposed as a new 
avenue for improving diagnosis, prognosis and immunotherapy for PCa.
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Background
Prostate cancer (PCa) is the second most common can-
cer in men worldwide [1]. Metastatic PCa is not curable 
by surgery and is resistant to chemotherapy and ionizing 
radiation [2] eventually leading to death [3]. Similarly to 
most solid tumors, PCa tissues are characterized by low 
oxygen tension–hypoxia–that in PCa is a marker of poor 
clinical prognosis [4].
It has been generally accepted that microenviron-
mental hypoxia is among the reasons for resistance to 
treatment; it reduces the rate of cell proliferation and 
modulates numerous properties of cells known to pro-
mote resistance to chemotherapy and radiation [5–7]. In 
addition, hypoxia is associated with increased chromo-
somal instability, gene amplification, down-regulation of 
DNA damage repair pathways, and altered sensitivity to 
DNA damaging agents [8, 9] contributing thus to cancer 
phenotype.
Hypoxia triggers mechanisms that tend to reinstate 
oxygen homeostasis by changes in gene expression medi-
ated mainly by the hypoxia-inducible factors (HIFs). 
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HIFs are heterodimeric proteins, each composed of one 
of the three α subunits and the single β subunit resulting 
in HIF-1, HIF-2 and HIF-3 [10]. In hypoxia, HIF-1 and 
HIF-2 rapidly accumulate and translocate to the nucleus 
[11] to activate genes involved in endothelial cell prolif-
eration, migration, permeability, survival, and response 
to radiotherapy and chemotherapy [12–15].
Changes in oxygen tension (pO2) modulate innate and 
adaptive immunity as well [16, 17], but it is less clear 
whether hypoxia contributes to the difficulties in devel-
oping effective cancer immunotherapy [18]. While most 
immunotherapy studies have focused onto boosting 
immunity (in the face of cancer–associated immunosup-
pression [19–21]), comparatively less attention has been 
paid to the role of hypoxia in modulating the expression 
of tumor–associated antigens (TAAs); this could be par-
ticularly germane for the vaccines consisting of whole 
cancer cells hitherto commonly prepared under standard 
(normoxic) tissue culture conditions [22]. Since pO2 val-
ues at standard culture conditions are much higher than 
those in hypoxic tumors, current normoxically cultured 
cell-based vaccines express antigens of unknown rele-
vance to tumors in situ.
It has been reported recently that TAAs in human 
hypoxic glioma cells were more akin to TAAs in tumors 
in situ than to TAAs in cells cultured in air [23, 24]. The 
relevance of pO2 in modulation of immunogenicity of 
PCa cells is unknown; hence, we studied whether the 
TAAs in hypoxic PCa cells are different from normoxic 
PCa cells. Revealing oxygen-sensitive PCa-specific anti-
gens could have important implications for development 




All samples were collected retrospectively in the Mayo 
Clinic, Rochester, MN, USA and the University of Missis-
sippi Medical Center, Jackson, MS, USA. The study pro-
tocol is in compliance with the Declaration of Helsinki 
and was approved by the corresponding Institutional 
Review Boards. Following surgical resection or dona-
tion, sample aliquots were prepared, immediately fro-
zen at −80 °C, and stored until use. For identification of 
PCa-associated antigens in hypoxic PCa cell lysates and 
patient immune reactivity by 2-DE Western blot experi-
ments, plasma from 25 early-stage PCa patients was uti-
lized. Clinicopathological characteristics of PCa patients 
utilized in those experiments are summarized in Table 1. 
For the constitution of control groups, plasma provided 
by collaborators at Mayo Clinic, Rochester was obtained 
from 20 healthy age-matched volunteers, patients suf-
fering from colon cancer (n = 10), lung cancer (n = 10), 
or rheumatoid arthritis (n = 20). For 2-DE Western blot 
protocols, pools (n = 5) of plasma samples were prepared 
and tested for nonspecific binding to the nitrocellulose 
membrane. To evaluate levels of autoantibodies specific 
for TAAs in human plasma by ELISA, additional plasma 
samples from healthy controls (n = 56) and patients with 
PCa (n = 29), obtained from the University of Mississippi 
Medical Center were included among the specimens 
described above. A group of plasma samples from 20 
renal cell carcinoma patients, provided by collaborators 
Table 1 Clinicopathological characteristics of  prostate 
cancer patients utilized in 2-DE Western blot experiments
Age at surgery
 Number of cases 25
 Mean (SD) 61.5 (4.58)
 Median age, years (range) 61.0
 Q1, Q3 58.0, 65.0
 Range (55.0–72.0)
Pre‑op PSA
 Mean (SD) 5.8 (3.91)
 Median age, years (range) 5.0
 Q1, Q3 4.0, 6.3
 Range (1.7–20.5)
Clinical grade (GLEASON)
 Missing 0 (%)
 6 24 (96 %)
 7 1 (4 %)
 8 0 (%)
 9 0 (%)
Clinical T‑stage, 1997 TNM
 Missing 0 (%)
 T1C 16 (64 %)
 T2a 9 (36 %)
 T2b 0 (%)
 T34 0 (%)
Pathologic grade (GLEASON)
 Missing 0 (%)
 6 25 (100 %)
 7 0 (%)
 8 0 (%)
 9 0 (%)
Pathologic stage, 1997 TNM
 Missing 0 (%)
 T2aN0 8 (32 %)
 T2bN0 17 (68 %)
 T3aN0 0 (%)
 TxN+ 0 (%)
Treatment‑prior to surgery
 Missing 0 (%)
 No 25 (100 %)
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at Mayo Clinic, Rochester was utilized as an additional 
control group. For ELISA protocols, plasma samples were 
individually assayed.
Cell culture
Cultured human PCa cell lines designated VCaP, LNCaP 
(American Type Culture Collection, Rockville, MD, 
USA), and C4-2B (Characterized Cell Line Core Facility, 
University of Texas MD Anderson Cancer Center) were 
seeded into T25 or T75 flasks (BD Falcon, Bedford, 
MA). LNCaP cells originate from a lymph node metas-
tasis [25]. VCaP cells were generated from a vertebral 
metastatic lesion and harbor the TMPRSS2-ERG fusion 
(present in 40–60  % of PCa patients) [26, 27]. C4-2B 
cells represent a human bone metastatic PCa and are 
a derivative of LNCaP cells with more aggressive char-
acteristics [28]. The interest in those cell lines is also 
based on their ample use by PCa researchers and the 
utilization of immortalized cells lines as components 
of heterologous whole cell PCa vaccines [29]. Cells 
were maintained in phenol-red supplemented RPMI-
1640 (LNCaP and C4-2B) and DMEM (VCaP) medium 
containing 10  % heat-inactivated fetal bovine serum 
(Cellgro, Manassas, VA, USA) at 37  °C in humidified 
air enriched with 5  % CO2 and with O2 content either 
20  % (approximately 20  kPa, normoxic), 2  % (approxi-
mately 2 kPa, hypoxic), or 1 % in some cases in a CO2 
incubator (Binder, Germany). The cells were trypsi-
nized at 80–90  % confluence and plated at the density 
of 25,000 cells/cm2 (LNCaP and VCaP) or 12,000 cells/
cm2 (C4-2B). The medium was not refreshed during 
the course of the experiments. To evaluate cell viability, 
cells excluding trypan blue were counted by the aid of a 
hemocytometer.
ELISA measurement of cytokines and autoantibodies
Concentrations of vascular endothelial growth factor 
(VEGF), a marker of hypoxia, were measured in condi-
tioned culture media by ELISA (R&D Systems, Min-
neapolis, MN, USA). Levels of autoantibodies specific 
for heat-shock protein (HSP) 60 and HSP70 in human 
plasma were measured using IgG/A/M ELISA kits for 
HSP60 and HSP70, respectively (Enzo Life Sciences, 
Plymounth Meeting, PA, USA). Provided recombinant 
antigens were used as standards. Autoantibodies for 
heterogeneous nuclear ribonucleoprotein L (hnRNP L) 
were assayed using the pertinent ELISA kit (CUSABIO, 
Wuhan, China). The assays were conducted according 
to manufacturers’ guidelines. Plasma from healthy vol-
unteers and patients with PCa, colorectal cancer, lung 
cancer, renal cell carcinoma, or rheumatoid arthritis were 
diluted thousand-fold. The cutoff reactivity for disease 
was defined as any value that was higher than the mean 
of the value plus twofold of standard deviation observed 
in normal plasma.
Quantitative RT‑PCR
Total mRNA was isolated using RNeasy Mini kit (Qia-
gen, Germantown, MD, USA) according to manufactur-
er’s instructions: One µg RNA was reversely transcribed 
using SuperScript III First Strand Synthesis (Invitrogen, 
Grand Island, NY, USA). Subsequently, quantitative PCR 
was performed with a LightCycler 480 SYBR Green I 
Master (Roche, Madison, WI). Levels of mRNA were 
normalized relative to the levels of control ribosomal 
protein S28 (RPS28) mRNA [30]. Data were analyzed by 
the Delta Delta Ct (2−∆∆CT) method using Excel program. 
Primer sequences used were (forward/reverse): VEGF-α: 
agtccaacatcaccatgcag/ttccctttcctcgaactgattt; and RPS28: 
ttttggagtcagagcgagaag/agcatctcagttacgtgtgg.
Cell lysate preparation and labeling
LNCaP and VCaP cells grown in T75 flasks for four days 
and seven days, respectively, were washed with cold 
phosphate-buffered saline (PBS), scraped and centri-
fuged in PBS at 380×g for 5 min at 4 °C. Cells from up to 
3 T75 flasks were resuspended in 1 mL PBS and centri-
fuged at 16,000×g for 1 min. To the pellet, 1.5 volume of 
2D lysis buffer (7 M urea, 2 M thiourea, 4 % w/v CHAPS 
and 40 mM Tris, pH 8.5, 1 × nuclease mix; GE Health-
care, Pittsburgh, PA) was added together with 1x  pro-
tease inhibitor cocktail set III (per mL of 2D lysis buffer 
containing 10  µL of 100x  protease inhibitor cocktail set 
III; Calbiochem, San Diego, CA, USA). Cells were soni-
cated on ice for 30 min followed by continuous shaking 
for 45 min at 4 °C. Lysates were centrifuged at 24,000×g 
for 10  min. Supernatants were collected and saved at 
−80 °C. Protein concentration was determined by Brad-
ford assay (Bio-Rad, Hercules, CA, USA) using bovine 
γ-globulin (Pierce, Rockford, IL, USA) as standard. Prior 
to 2-DE, 50 µg of lysate protein was labeled with 400 pM 
of differential in-gel electrophoresis (DIGE) fluor Cy5 
minimal dye (GE Healthcare). Lysates were incubated 
with dyes for 30 min on ice in the dark. Labeling reaction 
was stopped by the addition of 1 μL of 10 mM lysine and 
incubation for 10 min on ice in the dark.
Two dimensional gel electrophoresis (2DGE) and silver 
staining
Fifty µg protein per sample was diluted in 2D lysis buffer 
(without inhibitors) containing 30  mM DTT, 1  % 3–10 
Pharmalyte ampholyte mixture and 0.25  % 3–10 non-
linear (NL) immobilization pH gradient (IPG) buffer 
(GE Healthcare, Pittsburgh, PA, USA). After shaking for 
30  min, the samples were dispensed into the isoelectric 
focusing tray, overlaid with 11 cm 3-10NL IPG strips and 
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mineral oil, passively rehydrated for 11  h, and focused 
for a total of 35,000 Vh (Protean IEF Cell, Bio-Rad). 
After isoelectric focusing, the strips were immersed in 
equilibration buffer containing 1 % DTT for 10 min, fol-
lowed by equilibration buffer with 2 % iodoacetamide for 
15 min. The second dimension was carried out on Crite-
rion 10 % gels (Bio-Rad) for 10 min at 140 V, followed by 
1 h at 200 V. To detect the fluor Cy5–stained spots, the 
gel was placed directly between glass plates in a Typhoon 
9410 variable mode imager (GE Healthcare) using 633-
nm excitation and 670-nm emission wavelengths (opti-
mal for detection of DIGE fluor Cy5). Additionally, 
electrophoresed proteins were visualized by silver stain-
ing. Images were analyzed and stained spots identified 
using PDQuest sofware (Bio-Rad) according to manufac-
turer’s protocols.
2D Western blotting
To identify PCa-associated autoantibodies, plasma sam-
ples were electrophoresed as described. Electrophoresed 
proteins were electro-transferred from the gel to nitro-
cellulose membranes (Bio-Rad) and blocked with pooled 
patient or normal plasma diluted 1/300 in blocking buffer. 
Subsequently the membrane was incubated with chicken 
anti-human IgG conjugated with HRP (diluted 1/3000 in 
blocking buffer; Abcam, Cambridge, MA, USA). After 
the addition of a chemiluminescent substrate (Thermo 
Fisher Scientific, Rockford, IL), membranes were imme-
diately exposed on a CL-Xposure film (Thermo Fisher 
Scientific) and scanned with an Epson Perfection 4490 
Photo scanner (Long Beach, CA, USA) for detection of 
spots.
Protein digestion and mass spectrometry
Spots of interest identified by PDQuest were excised 
from gels, destained with 100 mM ammonium bicarbo-
nate in 30 % acetonitrile until transparent and dried in a 
vacuum centrifuge. Proteins were proteolyzed with 25 ng 
of modified trypsin (Promega, Madison, WI, USA) in 
25 mM ammonium bicarbonate at 37 °C overnight. Pep-
tides were precipitated with 0.1 % trifluoroacetic acid and 
60  % acetonitrile, vacuum-dried and analyzed by Ultra-
flex II MALDI-TOF system (Bruker Daltonics, Bremen, 
Germany). Spectra were analyzed by Biotools MS soft-
ware (Bruker Daltonics) to perform peptide mass fin-
gerprinting. We identified the proteins in the SwissProt 
database for Homo sapiens using carbamidomethyl on 
cystein as the fixed modification and methionine oxida-
tion as variable modification.
SDS‑PAGE and Western blot of tumor tissue lysates
Protein extracts were prepared from frozen pros-
tate tissue obtained from PCa patients (n  =  8) and 
cystoprostatectomy patients (n  =  4; used as control). 
Cysprostatectomy is a surgical procedure in which the 
urinary bladder and prostate gland are removed. The 
procedure combines cystectomy and prostatectomy and 
occurred in our situation for bladder cancer tumors. Tis-
sues were homogenized in an IKA Work tissue homog-
enizer (Wilmington, NC, USA). Proteins were extracted 
from the homogenate with the AllPrep DNA/RNA/
Protein Mini Kit (Qiagen, Germantown, MD) accord-
ing to manufacturer’s guidelines. Thirty µg protein were 
resolved in a 10.5–14  % SDS-PAGE gradient gel, trans-
ferred to a nitrocellulose membrane and incubated with 
blocking buffer containing primary antibodies specific 
for HSP60 (diluted 1/250; Abcam), hnRNP L (1/5000; 
Abcam), and β-actin (1/5000; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA). Bound primary antibodies 
were visualized with HRP-conjugated antibodies spe-
cific for human IgG (diluted 1/1000–5000 in blocking 
buffer; Abcam, Cambridge, MA, USA). After addition 
of a chemiluminescent substrate SuperSignal West Pico 
(Thermo Scientific, Rockford, IL, USA), the membrane 
was immediately exposed on a CL-Xposure film (Thermo 
Fisher Scientific) and scanned with an Epson Perfection 
4490 Photo scanner to detect bands. Relative intensi-
ties of the bands were quantified using Image J Software 
(NIH online; Bethesda, MD); recorded values were nor-
malized to the intensity of the respective β-actin signal.
Statistics
All reported values represent three independent experi-
ments expressed as mean ± SEM. Data for cell prolifera-
tion, VEGF release, and mRNA expression were analyzed 
by two-way ANOVA (pO2 vs. day), followed by a post hoc 
Student–Newman–Keuls multiple-comparisons test. Dif-
ference in HSP60 and hnRNP L proteins between tumor 
and normal tissue lysates were analyzed by the Mann–
Whitney U test. Comparisons of plasma autoantibody 
levels for HSP60, HSP70 and hnRNP L among different 
patient groups were done using one-way ANOVA, fol-
lowed by a post hoc Student–Newman–Keuls multiple-
comparisons test (HSP60 and HSP70) or one-tailed t test 
(hnRNP L). A difference was considered significant at 
p < 0.05.
Results
PCa cells differ in sensitivity to hypoxia
To explore the effect of pO2 on cell viability of PCa cells, 
we exposed them to pO2 =  20  kPa or 2 kPa. Cells were 
counted as a function of time. The selection of cell lines 
utilized in this study is based on their distinct origin 
[25–27], representation of particular patients spectrum 
[25–27], and involvement as components PCa vaccines 
[29]. VCaP cells (Fig.  1a) showed a slow increase in cell 
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numbers with significant increase from basal levels at day 
7 (p < 0.05). Evaluation at day 11 evidenced twofold higher 
cell numbers in cells growing under hypoxia, relative to 
cells cultured in normoxic conditions (p < 0.05). Relative 
to VCaP cells, LNCaP cells (Fig. 1b) had a faster growth 
kinetics. Under normoxia, cells reached maximum num-
bers at day 4. At that time point, however, cells cultured in 
hypoxia had only close to a third of numbers relative those 
cultured in normoxic conditions (p < 0.05). Cell numbers 
did not experience further variation in LNCaP cultures 
under hypoxia. Similarly, C4-2B cells, the subline derived 
from LNCaP cells, had reduced viability when grown in 
pO2 = 2 kPa relative to that observed in cells growing at 
20  kPa. Independently of oxygen levels, the maximum 
number of C4-2B cells in cultures cells was reached at day 
4 (Fig. 1c). At that point, however, cells cultured in nor-
moxic conditions had 2.3-fold more cells when compared 
to cells growing in hypoxia (p < 0.05). Cell numbers under 
normoxia and hypoxia did not experience further varia-
tion (compared to that observed at day 4) until comple-
tion of the experiment (day 10; p < 0.05).
VEGF is a hypoxia-inducible gene associated with the 
growth, aggressiveness and down-modulation of anti-
tumoral immunity [31]. Assessment of the release rate 
of this pro-angiogenic factor to the conditioned media 
revealed distinct patterns of induction in PCa cells grow-
ing under hypoxia. VCaP cells (Fig. 1d) secreted VEGF at 
observable rates on day 3 (p < 0.05) reaching the maxi-
mum rate on day 5. This release rate was maintained up 
to day 11. In contrast, LNCaP cells cultured under low 
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Fig. 1 Effect of hypoxia on PCa cells. Effects on cell viability: VCaP (a), LNCaP (b) and C4‑2B (c) cells were cultured at pO2 = 1 or 2 kPa (filled circle) or 
20 kPa (circle). Alive cells were counted in triplicate flasks using trypan blue exclusion to differentiate dead cells. Effects on VEGF production: Rates 
of VEGF release in conditioned culture media were measured by ELISA for VCaP (d), LNCaP (e) and C4‑2B (f) cells. Assessment of VEGF transcripts: 
mRNA levels of VEGF were analyzed in VCaP (g), LNCaP (h) and C4‑2B (i) cells by qRT‑PCR. *p < 0.05 when data at hypoxia is compared to values 
at normoxia O2 at the same time point; 
#p < 0.05 when data at hypoxia or normoxia is compared to a previous time point within the same pO2; 
&p < 0.05 when a specific data point is compared to the point at day 0 within the same pO2
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oxygen (Fig.  1e) had a steady increase of VEGF release 
rate until day 6. At that time point, a tenfold increase 
(p  <  0.05) was observed relative to the values at day 
0. Measured release of VEGF decreased to 7.5-fold at 
day 8. C4-2B cells cultured under normoxia (Fig.  1f ) 
did not release VEGF until day 6. At that time point, 
nearly 2.5  pg/cell/day (p  <  0.05) VEGF was released; 
that rate remained constant until day 8. Cells growing 
at pO2  =  2  kPa, however, released higher VEGF faster 
relative to their counterparts growing at pO2  =  20  kPa 
(p  <  0.05). A maximum (8  pg/cell/day) was reached at 
day 6 (p  <  0.05) and maintained at day 8 (p  <  0.05). To 
assess the effect of transcriptional regulation on the 
observed release of VEGF, qRT-PCR was performed. 
Early induction of VEGF transcripts, nearly 45-fold in 
VCaP (Fig. 1g) and LNCaP (Fig. 1h) cells (at 2 days) and 
60-fold in C4-2B (Fig. 1i) cells (p < 0.05), was observed in 
all cell lines when cultured under hypoxia. In cells grow-
ing under normoxia, VEGF transcripts were also induced 
(nearly tenfold in LNCaP and C4-2B cells, p < 0.05). The 
induction of VEGF in cells growing in normoxia, how-
ever, was observed at later time points and at a lesser 
extent in comparison to cells cultured under hypoxia. 
All together, these results indicate that, in accordance to 
reported findings [32, 33], PCa cells exposed to low levels 
of oxygen exhibit increased viability and elevated expres-
sion of the angiogenic factor, VEGF.
Effects of hypoxia on immune reactivity of PCa cells
To determine if pO2 modifies the reactivity of autoanti-
bodies in CaP patient plasma, following published proto-
cols [34] we harvested the cells at their highest reached 
cell density (VCaP, day 7; LNCaP, day 4), prepared lysates 
and resolved them by 2DGE. One of the two identical 
gels was silver-stained and the other blotted onto a nitro-
cellulose membrane. As antibodies reactive with tumors 
are commonly found in patient plasma [35], we pooled 
the plasma from PCa patients (n = 5/pool) and reacted 
it with the blotted proteins. For controls, plasma from 
healthy individuals, patients suffering from lung cancer, 
colon cancer or rheumatoid arthritis was used, n  =  5/
pool. We found that PCa-patient plasma consistently 
bound to more spots of VCaP (Fig. 2) and LNCaP (Fig. 3) 
cells than did control plasmas. In some cases, the size of 
spots differed significantly when PCa plasma or healthy 
control plasma was used. To assess the molecular identity 
of the spots reacted with PCa plasma only, we excised the 
selected spots, digested them by trypsin, and analyzed 
then by MALDI-TOF mass spectrometry. Use of DIGE 
fluor Cy5 minimal dye facilitated alignment of the silver-
stained gel and the blotted membrane for spots selection. 
In VCaP cells we identified heat shock 70  kDa protein 
(HSP70), heat shock 60  kDa protein (HSP60), protein 
disulfide isomerase A3 (PDIA3), nuclear ribonucleopro-
tein (hnRNP L), and leucine-rich repeat-containing pro-
tein 47 (LRRC47) (Table 2). In LNCaP cells we identified 
HSP70, HSP60, hnRNP L, glucose-6-phosphate-1-de-
hydrogenase (G6PD), and dihydrolipoyl dehydrogenase 
(DLD) (Table 3).
For independent confirmation we focused on three 
antigens, HSP60, HSP70, and hnRNP L. Regardless of 
the cell line used as source of antigens, healthy plasma 
reacted with normoxic lysates weakly and only faint 
spots or no spots for all three antigens was observed. The 
reactivity to PCa plasma was increased, particularly for 
HSP60 and hnRNP L, relative to healthy control plasma. 
Remarkably for all three analyzed antigens, interaction 
with hypoxic PCa cell lysates increased reactivity rela-
tive to that observed against normoxic cell lysates. For 
example (Figs. 2, 3), plasma reactivity for HSP60 was aug-
mented 2 and eightfold in VCaP and LNCaP cells, respec-
tively. Reactivity of PCa plasma to HSP70 using lysates 
obtained from VCaP cells grown pO2 = 20 kPa was not 
observed, but it was noted when lysates from cells grown 
at pO2 = 2 kPa were used as source of antigens. Similarly, 
a sevenfold increase in immune reactivity to HSP70 was 
observed in lysates from hypoxically-expanded LNCaP 
cells when compared to that noted for cells expanded 
under normoxia. hnRNP L (7 and twofold in VCaP and 
LNCaP cells, respectively), had increased reactivity to 
PCa plasma when hypoxic cell lysates were used.
Reactivity was also studied in other tumors. In par-
ticular, antibodies specific for HSP70 and hnRNP L were 
detected in the plasma of lung cancer patients only when 
reacting with VCaP cell lysates obtained from cells grown 
at pO2 = 2 kPa. Antibodies against HSP60, in a pO2 inde-
pendent manner, were detected in the plasma of colon 
cancer patients (Fig.  2b). Autoantibodies specific for 
hnRNP L were detected at fourfold higher level in lung 
cancer plasma reacting with hypoxic LNCaP cell lysates, 
relative to the level found with normoxic lysates (Fig. 3b). 
Independent of the cell line used as source of antigens, 
plasma from rheumatoid arthritis patients did not have 
reactivity for the three analyzed antigens when cells 
were cultured under normal oxygen. Hypoxia, interest-
ingly, allowed reactivity of rheumatoid arthritis patients’ 
plasma against HSP70 when lysates obtained from 
VCaP cells provided antigens. These results suggest that 
hypoxia increased reactivity of PCa cell lysates to patient 
plasma.
Evaluation of plasma autoantibody levels of HSP60, HSP70, 
and hnRNP L
Next, we set out to determine, at the individual patient 
level, the frequency of autoantibodies for HSP60, HSP70, 
and hnRNP L. For this purpose we performed ELISA 
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tests. The assay allows for reproducible, accurate, and 
precise determination of IgG, IgA and IgM antibod-
ies (total) in plasma. Recombinant human protein (e.g. 
HSP60, HSP70, and hnRNP L) were bound to the wells 
of the plate to bind anti-human antibodies for the analyte 
of interest present in plasma. The captured anti-human 
antibodies were detected with a HRP conjugated goat 
polyclonal antibody specific for human IgG, IgA, and 
IgM molecules. The frequency of HSP60 autoantibodies 
(Fig. 4a; Table 4) was 13.0 % (7/54) in PCa, 1.3 % (1/76) 
in healthy controls, 7.14  % (1/14) in colorectal cancer, 
10.0 % (1/10) in lung cancer, 5.0 % (1/20) in renal cell car-
cinoma, and 0 % (0/17) in rheumatoid arthritis. Statistic 
difference was found only between PCa and healthy con-
trol groups (p < 0.05). These data suggest elevated HSP60 
autoantibody levels in the plasma from PCa patients. 
The frequency of HSP70 autoantibodies (Fig. 4b; Table 4) 
was 5.3 % (2/38) in PCa, 3.7 % (2/54) in healthy controls, 
7.14 % (0/10) in colorectal cancer, 20.0 % (2/10) in lung 
cancer, 5.0  % (1/20) in renal cell carcinoma, and 17.6  % 
(3/17) in rheumatoid arthritis. No statistic difference was 
found between control group and any cancer- or non-
cancer group. The frequency of hnRNP L autoantibod-
ies was 5.3  % (2/38) in PCa and 6.1  % (3/49) in healthy 
controls (Fig. 4c; Table 4). We did not evaluate hnRNP L 
autoantibodies in other diseases.
Higher levels of hnRNP‑L proteins in PCa tissues
To test the possibility that the immune reactivity of 
selected PCa-associated antigens in plasma was due to 
elevated expression of PCa-specific antigens in tumor 
tissues, we analyzed levels of HSP60 and hnRNP L in 
tumor tissue lysates using Western blot. Protein lysates 
were prepared from prostate tissues obtained from 
patients suffering PCa or cystoprostatectomy (controls). 
Separated proteins were transferred onto a nitrocellulose 






pO2 = 2 kPa VCaP cell lysates










a Representative silver staining image of VCaP cell lysates following two dimensional electrophoresis
PDIA3 
LRRC47
HSP60 HSP70 hnRNP LHSP60 HSP70
pO2 = 20 kPa VCaP cell lysates
Fig. 2 Identification of PCa‑associated antigens in hypoxic VCaP cell lysates and patient plasma immune reactivity. VCaP cells were cultured at 
pO2 = 2 kPa and 20 kPa conditions for 7 days. Cell lysates were prepared and 50 μg proteins were loaded on pH 3–10 NL IPG strips for 2DGE. One 
set of gels was silver stained and other set was transferred to nitrocellulose membranes (a), incubated with pooled plasma from patients with PCa, 
colon cancer, lung cancer, rheumatoid arthritis (an autoimmune disease), and age matched healthy controls. Following incubation with chicken 
anti‑human IgG‑HRP, spots were identified by chemiluminescence (b). The arrowheads indicate protein spots of interest
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membrane and blotted against anti-human HSP60 and 
hnRNP L monoclonal antibodies. The level of HSP60 
(Fig.  5a) and hnRNP L (Fig.  5b) proteins in PCa tumor 
tissues was close to twofold higher (p < 0.05), compared 
to control prostate tissue. These data suggest that pro-
tein expression for the selected potential PCa-associated 
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a Representative silver staining image of LNCaP cell lysates following two dimensional electrophoresis







hnRNP LHSP60 HSP70hnRNP LHSP60 HSP70
pO2 = 2 kPa LNCaP cell lysatespO2 = 20 kPa LNCaP cell lysates
DLDG6PD
Fig. 3 Identification of PCa‑associated antigens in hypoxic LNCaP cell lysates and patient plasma immune reactivity. LNCaP cells were cultured at 
pO2 = 2 kPa and 20 kPa conditions for 4 days. Cell lysates were prepared and 50 μg proteins were loaded on pH 3–10 NL IPG strips for 2DGE. One 
set of gels was silver stained and other set was transferred to nitrocellulose membranes (a), incubated with pooled plasma from patients with PCa, 
colon cancer, lung cancer, rheumatoid arthritis (an autoimmune disease), and age matched healthy controls. Following incubation with chicken 
anti‑human IgG‑HRP, spots were identified by chemiluminescence (b). The arrowheads indicate protein spots of interest
Table 2 Potential PCa-associated antigens identified in VCaP cells
Protein name FASTA accession number MW (kDa)
Heat shock 70 kDa protein 4 (HSP70) P34932 94.3
60 kDa heat shock protein (HSP60) P10809 61.3
Protein disulfide isomerase A3 (PDIA3) P30101 56.8
Heterogeneous nuclear ribonucleoprotein L (hnRNP L) P14866 64.1
Leucine‑rich repeat‑containing protein 47 (LRRC47) Q8N1G4 63.5
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Discussion
We investigated the effect of hypoxia on the antigenic 
landscape in commonly used human PCa cell lines. As 
expected, hypoxia modified cell viability and promoted the 
release of the pro-angiogenic factor, VEGF. Use of a sero-
logic approach and combined 2DGE expression profiling 
of PCa cells and Western blot with PCa patient plasma 
allowed identification of autoantibodies to PCa-associated 
antigens. Hypoxia increased the immune reactivity of 
plasma to PCa cell lysates. Some of these, hypoxia-reactive, 
TAAs were identified. In particular, we identified HSP60 as 
a valuable TAA with potential as a tumor marker in PCa 
tissues. Overall, our studies suggest that tumor–associated 
hypoxia is a relevant determinant of tumor antigenicity.
Table 3 Potential PCa-associated antigens identified in LNCaP cells
Protein name FASTA accession number MW (kDa)
Heat shock 70 kDa protein 4 P34932 94.3
60 kDa heat shock protein (HSP60) P10809 61.3
Heterogeneous nuclear ribonucleoprotein L (hnRNP L) P14866 64.1
Glucose‑6‑phosphate‑1‑dehydrogenase (G6PD) P11413 59.2
Dihydrolipoyl dehydrogenase (DLD) P09622 54.1


































































































Fig. 4 Levels of Hsp60, Hsp70 and hnRNP L autoantibody in human plasma. Autoantibodies to HSP60 (a), HSP70 (b) and hnRNP L (c) were quan‑
titated in plasma by ELISA using recombinant antigens as standards. Healthy controls (filled circle) and patients with PCa (filled square), colorectal 
cancer (filled triangle), lung cancer (filled inverted triangle), renal cell carcinoma (filled diamond), and rheumatoid arthritis (circle). Plasma samples were 
diluted to 1/1000. The cutoff of reactivity was defined as the mean of sample plus twofolds of standard deviation from normal plasma. The level of 
significance was set at p < 0.05 between healthy control and PCa groups
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Low pO2 is commonly associated with tumor aggres-
siveness. For instance, hypoxia impacts the prolifera-
tion of rapidly-growing malignant tumors in  vivo [36] 
and in vitro [37]. Although there were no effects on cell 
viability during the first 4 days in LNCaP and its deriva-
tive, the subline C4-2B, the cells in the hypoxic condition 
grew slower than the corresponding cells under nor-
moxia (Fig. 1b, c). The result is consistent with previous 
reports in literature showing that LNCaP and PC-2 cells 
are less viable under hypoxia in comparison to normoxia 
[38, 39]. VCaP cells (Fig. 1a), on the contrary had higher 
cell numbers relative to cells cultured under normoxia. 
To date, no evaluation of the effects of low oxygen on 
the proliferation of VCaP has been reported. Our results 
therefore, are the first to suggest that hypoxia confers a 
survival advantage to the vertebral bone metastasis-
derived, VCaP cells. In additional experiments (data not 
shown), when cultured in low oxygen, the brain metasta-
sis-derived DU145 [40] and SV40-immortalized prostatic 
epithelial, P4E6 cells, derived from a primary prostate 
cancer biopsy [41], had reduced viability relative to cells 
growing in normoxia. On the contrary (data not shown), 
OnyCap23 cells, a subclone of the established prostate 
cell line PNT2-C2 [42] that was originally derived from 
a biopsy of a normal prostate gland, showed increased 
viability when cultured in hypoxic conditions. Of note, 
P4E6, OnyCaP23 and LNCaP cells have been previously 
utilized as components of an allogeneic whole cell PCa 
Table 4 Frequency of HSP60, HSP70 and hnRNP L autoantibodies in human plasma
Human plasma HSP60 HSP70 HnRNP L
N mg/ml 
(mean ± SD)




Positive cases  
(% of total  
cases)
N OD (mean ± SD) Positive cases  
(% of total cases)
Prostate cancer 54 34.7 ± 43.9 7 (13 %); P < 0.05 
compared to 
healthy controls
38 21.8 ± 13.1 2 (5.3 %) 38 0.267 ± 0.168 2 (5.3 %)
Healthy control 76 23.0 ± 25.8 1 (1.3 %) 54 21.1 ± 11.8 2 (3.7 %) 49 0.248 ± 0.117 3 (6.1 %)
Colorectal cancer 14 28.7 ± 25.5 1 (7.1 %) 10 19.0 ± 8.8 0 (0 %) – – –
Lung cancer 10 29.7 ± 34.4 1 (10.0 %) 10 34.9 ± 42.2 2 (20 %) – – –
Renal cell carci‑
noma
20 33.8 ± 24.2 1 (5.0 %) 20 26.4 ± 19.0 1 (5.0 %) – – –
Rheumatoid 
arthritis






















































Fig. 5 Expression of HSP60 (a) and hnRNP L (b) proteins in PCa tissues. Protein lysates extracted from frozen prostate tissues (8 samples from PCa 
patients and 4 samples from cytoprostatectomy patients) were separated by SDS‑PAGE. HSP60 and hnRNP L levels in the samples were identified by 
Western blot as described in the “Methods”. The level of significance was set at p < 0.05 between PCa and cytoprostatectomy samples
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vaccine, partially successful in suppressing progression of 
the disease [22]. One limitation of our study is the una-
vailability of data generated using other cell lines besides 
those from prostatic carcinoma origin as positive of neg-
ative controls for hypoxia induction. Inclusion of these 
cell lines would allow assessment of relevant aspects such 
as the relative extent of the response to oxygen in PCa 
cells and the disease-related specificity of our results. 
These differences, attributed to cell-specific manners to 
respond to changes in metabolism and survival environ-
ment, should be considered when seeking improvement 
of allogeneic PCa vaccines.
As a critical component of the response of cancer cells 
to hypoxia, we analyzed the expression of VEGF, involved 
in the tumor growth and progression [43]. Low oxygen 
within the tumor microenvironment upregulates VEGF 
[44], and therefore this pro-angiogenic factor can be used 
as a marker of hypoxia. Particularly, in PCa cells, VEGF 
is reported to be expressed and secreted at high levels 
under hypoxic conditions [33, 45, 46]. In consistency with 
these previous reports, our results showed that, inde-
pendent of the cell line used as source of VEGF, hypoxia 
enhanced VEGF release in PCa cells. This change, related 
to sustained increase >40–60 fold VEGF mRNA expres-
sion over basal levels (Fig.  1g–i), reflects the described 
[33, 45, 46] transcriptionally driven, induction of this 
pro-angiogenic factor under hypoxia. Similarly to VEGF, 
transcripts for hypoxia-inducible enzyme carbonic anhy-
drase 9 (CA9), overexpressed in cancer cells [47] and pro-
posed as a useful marker for hypoxic exposure and tumor 
aggressiveness [48] were assessed by us (data not shown). 
When measured, the transcripts of CA9 were 150- and 
fivefold higher in hypoxic compared to normoxic VCaP 
cells and LNCaP, respectively. Altogether, our findings 
indicate that, in accordance to reported findings [49], 
PCa cells exposed to low levels of oxygen exhibit features 
associated with increased aggressiveness.
2DGE in combination with Western blot is a well-
established method to identify antigens [50]. In the pre-
sent study, we used this approach to separate and identify 
potential PCa-TAAs in whole cell lysates. As shown in 
Tables  2 and 3, the screening method demonstrated 
several protein spots that were specifically revealed by 
antibodies present in plasma from PCa patients. These 
proteins can be divided into two main categories based 
on their functions, i.e., metabolic enzymes (G6PD, and 
DLD) and molecular chaperones (HSP60, HSP70). Other 
candidate antigens included PDIA3 and hnRNP L. The 
metabolic requirements of cancer cells differ from that of 
their normal counterparts. To support their growth and 
proliferation, cancer cells adapt their metabolic processes 
to drive macromolecular biosynthesis [51, 52]. Therefore 
it is not surprising to see immune reactivity to metabolic 
enzymes in cancer patients. For example, higher level of 
G6PD [53] have been reported in sera and/or tumor tis-
sues from several cancer patients. Further, these meta-
bolic enzymes have been recognized as markers for TAA 
[54–58]. In all, our findings add to the reported findings 
and support the relevance of metabolic enzymes as mem-
bers of the tumor-specific antigenic landscape. PDIA3 
catalyzes oxidative protein folding and has a variety of 
effects on the yield of native lysozyme during the oxida-
tive refolding of the reduced, denatured protein [59, 60]. 
Although up-regulation of PDIA3 was reported in breast 
cancer [34, 61] and hepatocellular carcinoma [62] tissues, 
to the best of our knowledge, it is the first time for detec-
tion of PDIA3 antibodies in plasma from PCa patients.
Among the identified TAAs, HSP60 and HSP70 were 
expressed in the studied PCa cell lines. HSPs are a group 
of highly evolutionary conserved proteins, including 
constitutively and inducible protein chaperones [63]. 
Mammalian cells express HSPs in response to heat as 
well as many other stress stimuli, including hypoxia [64]. 
Because HSPs play essential roles in tissue homeostasis 
[65], it has been postulated that they contribute to the 
development of many diseases, including tumors [66–
68]. Up-regulated expression of HSPs has been reported 
in several cancers, including PCa [69–75]. Consistent 
with 2DGE and Western blot analysis, ELISA showed a 
higher level of anti-HSP60 IgG/A/M in plasma from PCa 
patients than that from healthy controls (Fig. 4a; Table 4). 
These results suggest that HSP60 is a TAA in PCa and 
are in agreement with reported findings showing HSP60 
autoantibodies in sera from patients with breast can-
cer [34], colorectal cancer [76], and osteosarcoma [77]. 
Our data represent the first ones to suggest a specific 
humoral response against HSP60 in CaP. Further data 
analysis in an independent validation group is needed to 
evaluate the performance and diagnostic value of HSP60 
autoantibodies.
HSP70 is expressed only at low or undetectable levels 
in most normal cells and tissues, but its expression is rap-
idly elevated by a variety of physical and chemical stress-
ors [78]. Although there are many publications regarding 
the diagnostic, prognostic, and predictive implications 
of HSP70 in breast and several other cancers, its role in 
PCa remains unclear [79]. The value of HSP70 as PCa-
associated antigen was suggested by our TAA screening, 
but it was not successfully validated by ELISA. This result 
contrasts with previous findings suggesting HSP70 as a 
potential TAA in esophageal carcinoma [80] and hepato-
cellular carcinoma [62, 81]. In our hands, just like in the 
findings from Cornford and collaborators [74], HSP70 
was unaltered in the plasma of early stage PCa patients 
when compared with nonneoplastic prostatic epithelium. 
Regardless of these results, the authors indeed reported 
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diminished expression of HSP70 in morphologically 
advanced cancers. Our report adds to the published 
information [74] suggesting that patterns of HSP70 are 
not significantly altered in early stage PCa patients (used 
in our studies) and may be, therefore, differentially mod-
ulated as a function of disease progression.
Heterogeneous nuclear ribonucleoprotein L is an 
abundant RNA-binding protein implicated in many bio-
processes [82], including those related to control of the 
expression of hypoxia-associated genes. For example, 
a specific interaction of hnRNP L with VEGF mRNA is 
thought to play an important role in hypoxia-induced 
post-transcriptional regulation of human VEGF mRNA 
stability [83]. Several lines of evidence show that hnRNP 
L is involved in tumorigenesis. For instance, phosphoryl-
ated hnRNP L promotes expression of the antiapoptotic 
form of caspase-9 (an initiator caspase) and thereby con-
tributes to tumorigenesis [84, 85]. In PCa cells hnRNP 
L acts in mitosis as a src-associated 68  kDa (Sam68)-
interacting protein and regulates splicing in response to 
signaling cascades [86]. In the present study, autoanti-
bodies specific for hnRNP L were detected in PCa plasma 
reacting both with VCaP (Fig. 2) and LNCaP (Fig. 3) cell 
lysates. ELISA analysis, however, did not reveal difference 
in plasma hnRNP L autoantibody levels between PCa 
and the healthy control groups (Fig. 4c; Table 4). Regard-
less of these results, evaluation of the levels of hnRNP L 
in tumor tissue lysates using Western blot revealed that 
along with HSP60, protein level of hnRNP L in a small 
number of PCa tumor tissues was twofold higher com-
pared to control prostate tissue (Fig. 5). These data trace 
back to tumor expression of HSP60, the TAA validated 
in plasma. Additionally, the results suggest that, despite 
the lack of relevant immune plasma reactivity, protein 
expression of hnRNP L in the tumor holds potential as 
marker and tumorigenic factor in PCa. Furthermore, 
this finding illustrates the importance of validation in the 
assessment of tumor markers. Since selection of proper 
relevant antigens is key for the generation of target-spe-
cific cancer vaccines, we think our results suggest that 
hn-RNP L may not be a good antigen to further pur-
sue. Additional work, however is needed to settle the 
discussion.
Our analysis consistently revealed increased plasma 
reactivity when lysates from PCa cells cultured under 
hypoxia were used as source of antigens. These find-
ings, despite of the limitation of lacking control lysates 
obtained from cells from non-prostatic origin, under-
score relevant concepts. On one side, they sustain the 
reported immunogenic nature of PCa tumors [87] ini-
tiators, in this case of autoimmune responses against 
prostate antigens. On the other side, the results suggest 
a role of hypoxia as an immunostimulatory factor with 
potential to expand the antigenic landscape of clinically 
relevant TAAs for diagnosis and treatment of PCa. In 
this study, plasma of early stage, newly diagnosed PCa 
patients was utilized as source of TAAs. This was done 
in order to avoid confounding effects of advanced disease 
or treatments on immune reactivity [88]. As source of 
antigens we used cell lines of metastatic origin. It is cer-
tainly possible that those cell lines provided an antigenic 
landscape that may be different from that recognizable in 
plasma from newly diagnosed patients. This is another 
limitation of our experimental approach. Future studies 
should be focused on validating the potential of the iden-
tified TAAs. This should be done in scenarios including 
disease progression and/or established or experimen-
tal therapeutic modalities. Critical questions needing 
answer in terms of determinants of tumor immunogenic-
ity, or the ability of the immune system to induce adaptive 
responses to tumors, pertain to the upstream tumor spe-
cific mediators that initiate the cascade of events that lead 
to immunosuppression [89]. Tumor hypoxia, represents 
an important impediment to immune-mediated control 
of tumor growth [5]. Our results indicate that hypoxia 
increases detection of humoral autoimmune responses. 
The involvement of hypoxia in actively eliciting tumor 
immunity or playing and adjuvant role to elicit more 
effective immune responses is, however, unknown. In 
favor of this role, recent characterization of the immune 
responses in a murine model of glioma, led to the identi-
fication of oxygen as an “immunologic switch” affecting 
both cell-mediated and humoral immune responses elic-
ited by tumor cell lysates [23]. These data, further vali-
dated using tumor lysates from patients obtained under 
hypoxic culture as source of the antigenic repertoire [24], 
demonstrate the ability of low oxygen to enhance immu-
nogenicity. Our results, supported by the reported find-
ings [23, 24], allow us to propose that PCa vaccines made 
by expansion of primary tumor cells in low oxygen will 
enhance cell-based therapeutic vaccines for PCa. This 
premise deserves further investigation. Utilization of 
three dimensional culture systems such as matrigel or 
spheroids [33] and patient-derived primary PCa tumors 
as source of antigens, or implementation of an animal 
model to evaluate immune responses in vivo are neces-
sary to validate our proposal. Use of a 2-dimensional cul-
ture system is a limitation of our study. Certainly the use 
of microenvironment-relevant experimental conditions 
would allow improvement in the identification hypoxia-
specific tumor-associated antigens. We focused our stud-
ies in PCa cell lines and use of 2-dimensional cultures 
because those conditions have been utilized previously to 
generate allogeneic PCa vaccines with limited beneficial 
effects in patients [18, 22, 41]. This decision was based on 
the rationale of providing the scientific community with 
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the proof of principle directing future studies geared into 
the improvement of current vaccines. Nevertheless, the 
tumor microenvironment-dependency of our findings 
is to be proven in future studies. Use of relevant experi-
mental setups will allow us to demonstrate the ability of 
low oxygen to enhance immunogenicity or its ability to 
enhance cell-based therapeutic vaccines for PCa.
LNCaP and VCaP cells showed differences in expres-
sion of PCa-associated antigens. For instance, while 
HSP70, HSP60, hnRNP L and snRNP70 antigens were 
detected in both hypoxic cell lines, PDIA3 and LRRC47 
antigens were found only in hypoxic VCaP cells. Likewise 
G6PD, PHGDH, ALA and DLD were specifically detected 
in hypoxic LNCaP cells. The origin of these findings is 
based on the distinct nature of the cell lines utilized in 
our studies; LNCaP cells are originated from a lymph 
node metastasis [25] and VCaP cells are generated from 
a vertebral metastatic lesion and harbor the TMPRSS2-
ERG fusion (present in 40–60  % of PCa patients) [26, 
27]. Our results implicate that the cell-specific spectrum 
of PCa-associated antigens may be relevant for develop-
ment of more effective individualized prognostication 
and allogeneic cell-based immunotherapy. This statement 
is particularly relevant in the light of the high complexity, 
heterogeneity, and immune escape inherent to PCa [90].
Conclusions
The role of pO2 in tumor biology has been unappreci-
ated. Recently, tumor–associated hypoxia has been asso-
ciated with malignant progression, metastasis, resistance 
to therapy, and poor clinical outcome. Our results vali-
date the relevance of tumor-associated hypoxia in CaP 
immune-reactivity. More importantly, our findings define 
the potential of hypoxia as a tool in the development of 
markers and immunotherapeutic targets for PCa.
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